摘要
目的 探讨18^F-FDG PET-CT在评价弥漫大B细胞淋巴瘤(DLBCL)早期化疗反应中的应用价值.方法 56例DLBCL初诊患者,采用CHOP或R-CHOP方案化疗,分别于化疗前和化疗2个周期后进行18^F-FDG PET-CT检查.比较完全反应组(30例)、部分反应组(18例)和无反应组(8例)间的完全缓解率及每组化疗前后最大标准摄取值(SUVmax).结果 完全反应组、部分反应组和无反应组的完全缓解率分别为93.33%(28/30)、66.67%(12/18)和12.50%(1/8),三组间差异有统计学意义(x2=21.62,P<0.005).完全反应组的完全缓解率高于部分反应组(x^2=4.00,P< 0.05);完全反应组、部分反应组的完全缓解率高于无反应组(x^2=18.58,P<0.005;x^2=4.51,P<0.05).完全反应组化疗前SUVmax为19.00±5.03,化疗后PET-CT示所有病灶均消失;部分反应组化疗前SUVmax为17.18±4.68,明显高于化疗后的5.20±3.35,差异有统计学意义(t=14.32,P<0.001);无反应组化疗前SUVmax为16.63±6.49,与化疗后的13.81±5.95相比,差异无统计学意义(t=2.073 2,P>0.05).结论 18FFDGPET-CT在DLBCL化疗早期有助于预测化疗疗效.
Objective To assess the value of 18^F-FDG PET-CT in monitoring early chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL).Methods 56 patients with DLBCL received 18^F-FDG PET-CT before and after 2 cycles of chemotherapy (CHOP or R-CHOP protocol).The patients were divided into 3 groups,including complete response group (30 cases),partial response group (18 cases) and no response group (8 cases).The x^2 test was performed on comparison of complete remission rate and the t test on SUVmax.Results Complete remission rate of complete response group,partial response group and no response group were 93.33 % (28/30),66.67 % (12/18),and 12.50 % (1/8),respectively (x^2 =21.62,P 〈 0.005).Complete remission rate of complete response group was higher than that of partial response group (x 2 =4.00,P 〈 0.05).Complete remission rates of complete response group and partial response group were higher than that of no response group (x2 =18.58,P 〈 0.005; x^2 =4.51,P 〈 0.05).A significant difference was observed in SUVmax of partial response group before and after chemotherapy (17.18±4.68 vs 5.20±3.35,t =14.32,P 〈 0.001) and no obvious difference was showed in SUVmax of no response group between before and after chemotherapy (16.63±6.49 vs 13.81±5.95,t =2.073 2,P 〉 0.05).Conclusion 18F-FDG PET-CT is very useful and helpful for predicting early chemotherapy response in DLBCL.
出处
《白血病.淋巴瘤》
CAS
2014年第6期354-357,共4页
Journal of Leukemia & Lymphoma
基金
山西省肿瘤医院院所基金(201107)